1452 ORAL The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer

首页> 外文期刊>European Journal of Cancer Supplements >1452 ORAL The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer

【24h】

1452 ORAL The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer

机译：1452 ORAL多目标激酶抑制剂苹果酸舒尼替尼（SU11248）：转移性肾细胞癌患者药理活性的可溶性蛋白生物标志物

获取原文

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2005年第2期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. [J] . Ayllon J, Beuselinck B, Morel A, Cancer investigation . 2011,第4期

机译：苹果酸舒尼替尼（一种口服多靶受体酪氨酸激酶抑制剂）治疗转移性肾细胞癌患者后的长期反应和术后完全缓解。
2. 797 ORAL Sunitinib malate (SU11248) shows antitumour activity in patients with metastatic renal cell carcinoma: updated results from phase II trials [J] . European Journal of Cancer Supplements . 2005,第2期

机译：797口服苹果酸舒尼替尼（SU11248）在转移性肾细胞癌患者中显示抗肿瘤活性：II期试验的最新结果
3. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. [J] . Burstein HJ, Elias AD, Rugo HS, Journal of Clinical Oncology . 2008,第11期

机译：苹果酸舒尼替尼（一种口服多靶点酪氨酸激酶抑制剂）在先前用蒽环类和紫杉烷类治疗的转移性乳腺癌患者中的II期研究。
4. Stilbene analogues as inhibitors of breast cancer Stem cells through P-glycoprotein efflux; A 3D quantitative structure-activity relationship study (Inhibitory activity of stilbenes analogues on breast cancer stem cells) [C] . Anushree Tripathi, Krishna Misra 2016 International Conference on Bioinformatics and Systems Biology . 2016

机译：Stilbene类似物通过P-糖蛋白外排作为乳腺癌干细胞的抑制剂； 3D定量结构-活性关系研究（Stilbenes类似物对乳腺癌干细胞的抑制活性）
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship for the matrix metalloproteinase inhibitory effect of COL-3 following oral administration to patients with refractory metastatic cancer. [D] . Rudek, Michelle Ann. 2001

机译：口服给予难治性转移癌患者后，COL-3对基质金属蛋白酶抑制作用的药代动力学与药效关系的评价。
6. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [O] . Samuel E DePrimo, Carlo L Bello, John Smeraglia, 2007

机译：舒尼替尼在转移性肾细胞癌患者中药理活性的循环蛋白生物标志物：VEGF和VEGF相关蛋白的调节
7. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [O] . Samuel E DePrimo, Carlo L Bello, John Smeraglia, 2007

机译：舒尼替尼在转移性肾细胞癌患者中药效活性的循环蛋白生物标志物：VEGF和VEGF相关蛋白的调节
8. Identifying Physiological Substrates of the Snf-1-Related Kinase Hunk: New Biomarkers of Kinase Activity and Therapeutic Targets in Metastatic Breast Cancer. [R] . Bieberich, C. J. 2011

机译：鉴定snf-1相关激酶Hunk的生理基质：转移性乳腺癌激酶活性和治疗靶点的新生物标志物。

1452 ORAL The multitargeted kinase inhibitor sunitinib malate (SU11248): soluble protein biomarkers of pharmacodynamic activity in patients with metastatic renal cell cancer

著录项

引文网络

相似文献

相关主题

期刊订阅